Clinical Impact of New Data From Boston 2016

November 11-15, 2016; Boston, Massachusetts
In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File Size: 581 KB
Released: November 30, 2016


Educational grant provided by:
Merck & Co., Inc.
Gilead Sciences

Related Content

Download this PDF guide outlining key information on HCC risk assessment, screening, and surveillance in the setting of Hepatitis B infection

Robert S. Brown, Jr., MD, MPH Released: February 22, 2021

Expert CCO commentary on how to incorporate noninvasive methods to assess fibrosis into management of patients with HBV infection

Paul Y. Kwo, MD Released: February 18, 2021

Watch this brief presentation by Dr. Paul Kwo on interpreting serology, HBV DNA, and fibrosis assessments to determine HBV treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: February 15, 2022

Download free expert-authored slides reviewing AASLD guidance on HBV management pretreatment evaluation to determine treatment candidacy

Paul Y. Kwo, MD Released: February 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.